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PURPOSE. To investigate riboflavin concentration on enzymatic resistance following corneal
cross-linking (CXL).
METHODS. Ninety-six porcine eyes were divided into five groups in two treatment runs. Group
1 remained untreated. Group 2 received riboflavin 0.05%, group 3 riboflavin 0.1%, group 4
riboflavin 0.2%, and group 5 riboflavin 0.3%. Treated eyes underwent CXL with ultraviolet A
at 9 mW/cm2 for 10 minutes. Eight-millimeter discs from each cornea were submerged in
pepsin digest solution. In the first run, disc diameters were measured daily. After 10 days, dry
weights were recorded from five samples in each group. In the second run, dry weights were
recorded in five samples in each group at 10 and 20 days.
RESULTS. CXL-treated corneas took longer to digest than untreated (P < 0.001). Although eyes
treated with higher riboflavin concentrations generally took longer to digest, there were no
significant differences between groups (P ¼ 0.3). Dry weights at 10 days demonstrated, with
each increase in concentration, an increase in weight of residual undigested tissue (P <
0.001). In the second run, with each increase in riboflavin concentration there was an
increase in weight of residual tissue (P < 0.001) at 10 days. At 20 days, the dry weight was
lower with 0.05% riboflavin compared to 0.3% (P < 0.001) and 0.2% and 0.1% solutions (P <
0.05), with no other difference between groups.
CONCLUSIONS. There is a consistent dose-response curve with higher concentrations of
riboflavin achieving greater CXL efficacy, suggesting that manipulation of riboflavin dosage as
well as the UVA protocol can be used to optimize CXL.
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The current management of corneal ectatic diseases such askeratoconus depends on the severity and extent of the
degree of irregular astigmatism.1 Mild cases can be corrected
with spectacles and soft toric contact lenses.2 However, such
modalities are limited in their effectiveness as the cornea
becomes more irregular. In advanced disease, special soft, rigid
gas-permeable, and scleral contact lenses become a more
suitable solution to restore vision.3 Despite the use of such
special contact lenses, studies indicate that over 25% of patients
with keratoconus can progress to such an extent that they
require corneal transplantation,4 with this disease remaining
the most common indication for penetrating keratoplasty in
Europe, Australia, South America, Africa, and the Middle East.5
The introduction of cross-linking (CXL) has heralded a new
era in the treatment of corneal ectatic disorders. CXL utilizing
riboflavin/ultraviolet A (UVA) is now a widely established
intervention that has been shown to halt the progression of the
disease process in keratoconus, post-LASIK ectasia, and pellucid
marginal degeneration.6,7 The rationale of CXL is to enhance
the biomechanical rigidity of the cornea6,7 and its resistance to
enzymatic digestion8 by creating cross-links between both
collagen and proteoglycan molecules within the corneal
stroma.9–11 Not only does CXL appear to stabilize corneal
ectasia at a stage when contact lenses can still be utilized, it also
has been shown in many treated individuals to reduce
topographic steepness and corneal high-order aberrations,
resulting in improved vision.12 Indeed, a recent study in the
Netherlands demonstrated a significant reduction in the
number of corneal transplants for keratoconus following the
nationwide introduction of CXL.13
The standard CXL (SCXL) protocol, first described clinically
by Wollensak et al.7 in 2003, involves debridement of the
central 9 mm of corneal epithelium, followed by soaking the
exposed stromal surface with 0.1% riboflavin for 30 minutes
and irradiation with 370-nm UVA light with an intensity of 3.0
mW/cm2 for 30 minutes (a total dose of 5.4 J/cm2). This
protocol requires more than 1 hour of treatment time. To
shorten this procedure time, given the large potential numbers
of patients with progressive keratoconus requiring CXL and its
resultant burden to health service delivery, and to improve
patient and surgeon convenience alike, accelerated CXL (ACXL)
protocols have been introduced.14 These ACXL techniques are
based on the Bunsen-Roscoe law of photochemical reciprocity
and are modeled on the understanding that the same
photochemical effect can be achieved with a reduced
irradiation interval, provided that the total energy level is kept
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constant by a corresponding increase in irradiation intensity.15
However, as has been demonstrated with other photochemical
reactions, this law may be valid only within a certain dose
range and varies with different types of photochemical
processes.16 Certainly, while efficacy has been demonstrated,
it appears both in the laboratory17 and clinically18,19 that ACXL
may be less effective than SCXL, although the minimum
effective amount of CXL needed for stabilization of ectasia has
not yet been established.17,20
The precise reasons for the reduced efficacy of ACXL
protocols are unclear, and the exact mode of action of CXL at a
molecular level is undetermined.21 It is postulated that
riboflavin acts as a photosensitizer to produce both oxygen
singlets and riboflavin triplets,22 which then drive the CXL
process within the corneal stroma.23 What is understood is that
oxygen is essential to drive the process, and in the absence of
oxygen, CXL is impaired.24 It has been hypothesized that the
reduced efficacy associated with ACXL protocols might be the
result of more rapid oxygen depletion.25,26 Kameav et al.27
showed that, oxygen consumption occurs within seconds
during UVA irradiation and that following cessation of
irradiation, oxygen levels can take several minutes to be
restored. As such it has been hypothesized that by pulsing the
UVA light during irradiation, oxygen levels within the stroma
might be replenished/maintained so that the CXL process is
not compromised.28,29 Other investigators have advocated that
in addition to pulsing optimization of ACXL protocols can be
achieved by extending the UVA dosage by 30% to 40%.30,31
Indeed, in a laboratory study utilizing the same resistance to
enzymatic digestion methodology employed in this present
study, our group demonstrated increased efficacy with both
extended and pulsed UVA dosages with ACXL protocols,
although the results suggested that the distribution of cross-
links may be different compared to SCXL.23 As described
above, to date virtually all research directed at optimizing CXL
protocols has been targeted at manipulating the UVA irradia-
tion dosage of the treatment. Indeed, except for some
transepithelial CXL protocols,32 published CXL research,
including those with varying riboflavin formulations, has
almost universally maintained a riboflavin concentration of
0.1%. Almost 15 years after publication of the first clinical
paper,7 the optimal stromal riboflavin dosage for CXL is yet to
be determined.22 This present study aims to investigate this
issue by determining the efficacy of CXL using an enzymatic
(pepsin) resistance model in ex vivo porcine corneas with
varying concentrations of riboflavin (0.05%, 0.1%, 0.2%, and
0.3%).
METHODS
A total of 96 fresh porcine eyes were utilized in this study. All
had transparent corneas and an intact corneal epithelium on
inspection. They were obtained and transported on ice from a
local European Community licensed abattoir and used within
12 hours of death. The experiment was conducted using two
separate treatment runs to ensure the consistency of the
results. In the first run, 50 eyes were utilized, and in the
second, conducted 8 weeks later, 46 eyes were used.
Our pepsin digestion methodology has been published
previously.17,23 We chose this method as it facilitates relatively
slow digestion rates. This has allowed us in our past studies to
not only detect significant differences in the digestion rates in
terms of disc diameter measurements and time to complete
digestion but also to measure dry weights at 10 days, which has
highlighted significant differences between treatment proto-
cols that are not evident by just measuring disc diameters and
time to digestion alone.17,23 In addition, using this same
protocol we have repeatedly shown that there are no
differences in digestion times in nonirradiated corneas that
have not received riboflavin drops and those soaked in
riboflavin for 30 minutes.17,23 This allowed us in this study
to reduce the number of control groups and just use de-
epithelialized, nontreated, nonirradiated corneas as a sole
control group. In brief, following complete debridement of the
corneal epithelium using a single-edged razor blade, the eyes
were divided randomly into the five groups described in Table
1, in which group 1 (no riboflavin administered and no UVA
exposure) served as an untreated control and groups 2, 3, 4,
and 5 received varying concentrations of riboflavin solution
(0.05%, 0.1%, 0.2%, 0.3%, respectively) for a period of 30
minutes. All riboflavin solutions contained 20% dextran and
were identical in formulation except for the riboflavin
concentration. The riboflavin was applied using a 10-mm
suction ring/container (J2294; E. Janach srl, Como, Italy) that
was completely filled to its brim with the relevant riboflavin
solution concentration after being placed and suctioned over
the central cornea. Following the 30-minute riboflavin
diffusion period, all eyes in groups 2, 3, 4, and 5 underwent
irradiation using a CCL-VARIO corneal cross-linking UVA lamp
(Peschke Meditrade GmbH, Huenenberg, Switzerland) with a
wavelength of 365 nm and a 9.0-mm aperture, with an
intensity of 9 mW/cm2 for 10 minutes (total energy dose 5.4 J/
cm2). An accelerated treatment protocol was chosen, as we
needed to treat 44 eyes in each experimental run and wished
to use only one UVA irradiation device so that fluence levels
and UV beam profile were consistent between treatments. If
we had used the standard protocol of 3 mW/cm2 for 30
minutes, it would have taken 22 hours to complete the
treatments in radiation time alone. This would mean that the
eyes being treated last would be well over 24 hours old since
time from enucleation. Even though we treated one eye from
each group sequentially to minimize any effects of some eyes
being treated later than others, we did not want to include any
eyes in which treatment occurred after 24 hours. This was
undertaken to diminish any effects of natural decomposition,
endothelial and epithelial cell death with subsequent changes
in corneal hydration, and possible fungal/bacterial contamina-
tion. By using an accelerated treatment of 9 mW/cm2 for 10
minutes, we could reduce the total irradiation time to just over
7 hours and treat all eyes with 12 hours.
TABLE 1. Treatment Groups for the Two Separate Experimental Runs, Detailing the Differing Riboflavin Concentrations Utilized
Groups Riboflavin Soak Time CXL Time
No. of Eyes
Run 1 Run 2
1. Untreated corneas 30 minutes 9 mw/cm2 for 10 min 6 6
2. Riboflavin 0.05% 30 minutes 9 mw/cm2 for 10 min 11 10
3. Riboflavin 0.1% 30 minutes 9 mw/cm2 for 10 min 11 10
4. Riboflavin 0.2% 30 minutes 9 mw/cm2 for 10 min 11 10
5. Riboflavin 0.3% 30 minutes 9 mw/cm2 for 10 min 11 10
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Central corneal thickness measurements were taken man-
ually using a handheld ultrasonic pachymeter (Pachmate 55;
DGH Technology, Inc., Exton, PA, USA) after epithelial
removal, after riboflavin administration, and after UVA irradi-
ation in the treatment groups 2, 3, 4, and 5 in the first
experimental run (44 eyes).
On completion of the treatments, an 8-mm full-tissue-
thickness biopsy was trephined from the center of each
cornea. The corneal discs were placed in individual sealed
tubes containing 5 mL pepsin digest solution, 1 g ‡ 500 U/mg
pepsin from porcine gastric mucosa (Sigma-Aldrich Corp.,
Dorset, UK) in 10 mL 0.1 M hydrochloric acid at pH 1.2 and
incubated them in a water bath at 238C. As previous studies
have indicated that CXL results in cross-links not only at the
collagen fibril surface but also in the proteoglycan network
surrounding the collagen,11 we selected pepsin for enzymatic
digestion as it is a nonspecific endopeptidase that breaks down
both collagen and proteoglycan core proteins.
To reduce the risk of fungal/bacterial contamination,
sterility was maintained by undertaking the preparation of
the sample specimens with sterile instruments, which were
cleaned with an ethanol alcohol spray (Spiriclens DEB; Ecolab
Ltd., Leeds, UK) between specimen preparation. The sealed
tubes into which the corneal discs were placed were clean and
sterile prior to usage. To avoid contamination, from the water
bath, 30 mL chlorine-based disinfecting solution (Milton
sterilizing fluid; Milton Pharmaceutical Company, Bourne-
mouth, UK) was added to the bath water every 3 days and
the water replaced every 12 days. All instruments used when
handling samples for measurement were cleaned before and
between sample measurement and left to dry using ethanol
alcohol spray. At day 26, in the first experimental run the
pepsin digest solution in each sealed tube was replaced, both
to enhance further digestion and to attempt to maintain
sterility.
First Experimental Run
In the first experimental run (involving 50 eyes), electronic
digital calipers were used to perform daily measurements of
the longest diameter of the anterior surface of each corneal
disk. This was facilitated by microscopic examination at 103
magnification after the disk had been poured into a sterile petri
dish and separated from the pepsin digest solution using a
sterilized pipette. This magnified examination allowed the
longest diameter of the disc to be identified and precisely
measured with the electronic calipers. Measurements were
performed until the tissue could no longer be distinguished
from the surrounding pepsin solution, at which time point the
tissue was considered to have undergone complete digestion.
Measurements of anterior corneal disc diameter, rather than
stromal thickness, were used to assess the rate of enzymatic
digestion as the corneal discs underwent significant posterior
stromal swelling (in the vertical direction) during immersion in
pepsin digest solution, and the more-resistant anterior portion
of the cornea then separated from the posterior stroma after 4
to 6 days.17,23
To further evaluate the effect of different riboflavin
concentrations on corneal enzymatic resistance, five randomly
selected corneal discs from each CXL-treated group (groups 2,
3, 4, and 5) were removed from the pepsin digest solution after
10 days, placed in a 608C oven, and weighed daily until a
constant dry weight was obtained. The average dry weight was
then calculated for each group. There were no differences
between the groups in the mean times each of the groups were
in the oven (median 7 days). This methodology was
undertaken to ensure the samples were completely dehydrated
and the true dry tissue weight verified.
The remaining six discs in each of the CXL treatment
groups 2, 3, 4, and 5 remained in pepsin digest solution and
were measured daily, as described above, until digestion was
complete. At day 26 it appeared that the discs had stopped
digesting so the digest solution in each sealed tube was
replaced with freshly prepared pepsin digest solution (with the
same formulation as described previously), and the tempera-
ture of the water bath was increased to 268C to accelerate the
digestion process.
Second Experimental Run
To ensure the consistency of the results, a second experimen-
tal run of 50 eyes was conducted (Table 1). While previous
enzymatic digestion studies from our group17,23 have indicated
that the corneal disc diameter measurements appear to provide
information about the structural integrity of the most anterior
layers of the cornea, they can be subject to variation. This
occurs especially in the later stages of digestion when the
tissue tends to lose its circular shape and become irregular in
outline, making the longest diameter of the tissue difficult to
determine. As the dry weight measurements represent the total
mass of undigested tissue and negate any of the problems
associated with tissue shape and between-sample differences
in hydration, in the second experimental run we replaced
reliance on this more-reproducible methodology. In this run,
after being immersed in pepsin solution, the discs remained in
their sealed containers and were incubated at 238C until day
10, when five corneal discs from each CXL treatment group
(groups 2, 3, 4, and 5) were removed from the digest solution
and placed in the 608C oven until a constant dry weight was
obtained and the average corneal dry weight calculated for
each group. This process was repeated at 20 days, when the
remaining five corneal discs from each group were removed
from the pepsin digest, placed in the 608C oven, and their
constant dry weights recorded. The digest solution was not
renewed during this second run, and the water bath
temperature was maintained at 238C.
Statistical Analysis
Data are shown as average measurements (6 SD) for corneal
thickness, dry weight, and complete digestion time. Measure-
ments of corneal disk diameter are presented as a daily
cumulative measurement for each treatment group. Statistical
analysis was performed using a 1-way ANOVA and Bonferroni
multiple comparisons in a depth-wise manner. All statistical
analyses were performed with the Statistical Package for the
Social Sciences (SPSS Statistics 20; IBM, Armonk, NY, USA). A
probability value of P < 0.05 was considered significant.
RESULTS
Corneal Thickness
The average stromal thicknesses pretreatment (after epithelial
debridement), after riboflavin administration and after UVA
irradiation in the first experimental run are shown in Figure 1.
There was a significant decrease in thickness following CXL
(from pretreatment to after CXL) in all groups (P < 0.001), but
there were no differences in thicknesses between the groups
at any stage.
Time Taken for Complete Digestion
As previously reported,17,23 in all corneal discs significant
stromal swelling, in a posterior–anterior direction, was
documented within 24 hours of submersion in the pepsin
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digest solution. By 4 to 6 days, the anterior portion of each
corneal disc had separated from the posterior portion, and by
days 8 to 10 the posterior portion of each disc had undergone
complete digestion. The anterior portion of the corneal discs
persisted to allow daily measurements of diameter (Fig. 2;
Table 2).
The time required for complete digestion of the CXL-treated
corneal discs (groups 2, 3, 4, and 5) was significantly longer
than that required for the untreated specimens in group 1 (P <
0.001) (Fig. 2; Table 2). After 10 days, all untreated corneas
(group 1) had undergone complete digestion in both
experimental runs. Based on cumulative measurements of
corneal disc diameter for each treatment group, the irradiated
corneas treated with a higher concentration of riboflavin
appeared to take longer to undergo complete digestion than
those treated with lower concentrations of riboflavin. Howev-
er, this was largely due to the persistence of a minority of
samples within the higher riboflavin concentration groups
(Fig. 2), and the average time taken for complete digestion to
occur did not differ significantly between the CXL-treated
groups (P ¼ 0.3) (Table 2).
Dry Weight Measurements
After 10 days in the pepsin digest solution, only the CXL-
treated corneas remained, with all the untreated discs being
completely digested in both experimental runs (Fig. 2; Table
2).
First Experimental Run
In the first experimental run, there was a statistically significant
difference in dry weight measurements between all treated
groups (2, 3, 4, and 5) at 10 days (P < 0.001). For each group
with an increased riboflavin concentration, there was a
significant increase in the dry weight of residual undigested
corneal tissue, denoting an increased resistance of the tissue to
pepsin digestion (P < 0.001) (Fig. 3A; Table 3).
Second Experimental Run
Similarly, in the second experimental run, there was a
statistically significant difference in dry weight measurements
between all treated groups (groups 2, 3, 4, and 5) at 10 days (P
< 0.001). For each group with an increased riboflavin
concentration, there was a significant increase in the dry
weight of residual undigested corneal tissue, denoting an
increased resistance of the tissue to pepsin digestion (P <
0.001) (Fig. 3B; Table 3), with comparable average dry weights
for each of the treatment groups in the two experimental runs
(Table 3).
In the second experimental run at 20 days, measurement of
the average stromal dry weight was significantly lower in the
0.05% riboflavin treatment group (group 2) than in the 0.3% (P
< 0.001) and the 0.2% and 0.1% treatment groups (P < 0.05)
(groups 3, 4, and 5). There was no significant difference
between 0.1%, 0.2%, and 0.3% riboflavin/UVA treated groups
(groups 3, 4, and 5) at 20 days of digestion (Fig. 4; Table 4).
FIGURE 1. Corneal thickness measurements for each group in the first
experimental run are shown before treatment (after epithelial
debridement), following riboflavin administration for 30 minutes, and
after CXL (n¼ 11 per group). Data are shown as the mean value 6 SD.
FIGURE 2. The summed longest diameter of the corneal discs in each group in the first experimental run is shown as a function of time, which has
been normalized against the maximum time taken for corneas cross-linked using the standard 0.1% riboflavin formulation (42 days) to undergo
complete digestion. The discs appeared to stop digesting at approximately day 26 (normalized time of 0.62) so temperature was increased to 268C
and the digest solution renewed.
TABLE 2. Time in Days Taken for Complete Digest to Occur in All
Groups
Group
Time Taken for Complete Digestion to Occur
Minimum, d Maximum, d Average, d (6SD)
Untreated 6 10 8 (62)
0.05% Ribo/UVA 36 40 39 (62)
0.1% Ribo/UVA 36 42 39 (62)
0.2% Ribo/UVA 39 45 41 (62)
0.3% Ribo/UVA 38 46 41 (63)
Ribo/UVA, Riboflavin/UVA.
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DISCUSSION
SCXL has been shown to be efficient in arresting the
progression of corneal ectatic disease in most treated eyes
with up to 10 years follow-up.33,34 Although numerous
modifications of the epithelium-off CXL technique have been
postulated, these have almost universally focused on variation
in the UVA protocol and additives to the standard riboflavin
0.1% solution.21 Indeed, except for some epithelium-on CXL
formulations that utilize 0.25% riboflavin concentrations,32
virtually all currently used epithelium-off protocols use a
riboflavin concentration of 0.1%.21,22 Despite the passage of
almost two decades since the first human clinical CXL
treatments,7 the optimum riboflavin dosage for CXL is
undetermined,22 but to fully evaluate the efficacy and safety
of any drug, it is vital to determine its dose-response curve.35
There are multiple problems with determining this dose-
response curve, the not least of which is the difficulty in
measuring the biomechanical changes induced by CXL. As yet
there are no reliable ways to measure these changes in vivo,36 a
problem that compounded by the fact that any measurable
clinical changes take months to become evident and years to
stabilize.33,34 Even in vitro, the measurement of biomechanical
changes after CXL are beset with difficulty. Standard biome-
chanical measurement methodologies, such as stress-strain
extensiometry, have inherent deficiencies when applied to the
assessment of biological tissues such as the cornea.37 Such
biological tissues do not behave like metals and polymers with
homogeneous chemical/molecular bonds but rather have
nonhomogeneous chemical bonds and molecular interactions
that result in viscoelastic material properties. In addition, strip
specimens from corneas are originally part of a spherical
surface, so the length of the strip along its longitudinal
centerline is longer than its sides and there is variation in
thickness between the corneal center and its periphery.37 All
these factors can lead to poor measurement reliability, which
has led investigators to explore other potential methodologies
such as inflation techniques,38 scanning acoustic microsco-
py,39 and Brillouin microscopy,40 none of which have yet to
become a reliable gold standard measurement technique to
determine biomechanical changes after CXL.
An increase in activity of proteinase enzymes and reduction
of proteinase inhibitors have been identified in keratoconic
corneas41 and are liable to be important factors in the
pathophysiology of the condition and disease progression.
The main aim of corneal cross-linking is to halt the progression
of corneal ectasia. While cross-linking the macromolecules
within the corneal stroma undoubtedly augments its mechan-
ical strength, it also increases its resistance to enzymatic
FIGURE 3. (A) Average stromal dry weight of the untreated and treated
groups (n ¼ 5 samples per group) at day 10 in the first experimental
run. Error Bars: 61 SD. There was a statistically significant difference
in dry weights between all groups (P < 0.001) at 10 days. (B) Average
stromal dry weight of the untreated and CXL-treated groups (n ¼ 5
samples per group) at day 10 in the second experimental run. Error
Bars: 61 SD. There was a statistically significant difference in dry
weights between all groups (P < 0.001) at 10 days.
TABLE 3. Average Stromal Dry Weight of Control Group 1 and Treated
Groups 2, 3, 4, and 5 (n ¼ 5) at Day 10 in First and Second
Experimental Runs
Group
Mean Dry Weight After 10 Days
of Digestion, mg 61 SD
Run 1 Run 2
Untreated 0 0
0.05% Ribo/UVA 1.4 6 0.16 1.08 6 0.45
0.1% Ribo/UVA 2.5 6 0.16 2.68 6 0.19
0.2% Ribo/UVA 3.4 6 0.14 3.42 6 0.32
0.3% Ribo/UVA 4.04 6 0.18 3.86 6 0.54
FIGURE 4. Average stromal dry weight (milligrams) of control group 1
and treated groups 2, 3, 4, and 5 (n ¼ 5) at day 20 in a second
experimental run. Error Bars: 61 SD. The average stromal dry weight
was significantly lower in the 0.05% riboflavin treatment group (group
2) than in the 0.3% (P < 0.001) and the 0.2% and 0.1% treatment
groups (P < 0.05) (groups 3, 4, and 5).
TABLE 4. Average Stromal Dry Weight of the Untreated and CXL-
Treated Groups (n ¼ 5 samples per group) at Day 20 in the Second
Experimental Run
Group
Mean Dry Weight at 20 Days
in Second Experimental Run, mg 61 SD
Untreated 0
0.05% Ribo/UVA 0.68 6 0.33
0.1% Ribo/UVA 1.3 6 0.28
0.2% Ribo/UVA 1.3 6 0.25
0.3% Ribo/UVA 1.86 6 0.71
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digestion. Spoerl et al.42 were the first to demonstrate this
increased resistance of the corneal stroma to enzymatic
digestion after CXL. The ability of CXL to increase corneal
stromal resistance to enzymatic digestion can therefore be
expected to be a significant factor with regard to efficacy of the
procedure in halting disease progression. To what extend and
precisely how resistance to enzymatic digestion and increase in
biomechanical strength after CXL are responsible for and
contribute to its efficacy is yet undetermined, but both can
undoubtedly be used as a measure of CXL efficacy. It is for such
reasons, as well as poor measurement reliability of current
methods of corneal biomechanical assessment (which we
discussed above), that in this study we employed an enzymatic
digestion methodology. We have previously demonstrated the
efficacy of this methodology in determining differences in both
ACXL and epithelium-on CXL protocols compared to
SCXL.17,23
We employed two experimental runs in this study to ensure
consistency and verify our dry weight measurements, as well as
to simplify and improve our methodology. While daily
measurements of the disc diameters until digestion do provide
information about the structural integrity of the anterior layers
of the cornea to which CXL is directed,17,23 their measure-
ment, as well as being time-consuming, is subject to variation.
This is especially true in the later stages of digestion, when the
repeatability and hence reliability of the measurements are
reduced due to the smaller dimensions of the tissue and its
increasingly irregular outline. In addition, with time the pepsin
solution in which the discs are immersed loses its digestive
activity. Indeed, in the first experimental run we perceived that
the discs had stopped digesting at about day 26; therefore, in
order to complete the experiment, we had to renew the pepsin
solution. As dry weight measurements, which represent the
total mass of undigested tissue, were found to be highly
reproducible because they negate any problems associated
with within-sample variations in corneal thickness, shape, and
between-sample differences in hydration, in the second
experimental run we relied solely on this methodology and
collected dry weight measurements at day 10 and day 20 of
digestion.
All CXL-treated eyes in our study received an application of
an iso-osmolar riboflavin solution containing 20% dextran.
Consistent with previous studies,17,23,43 this resulted in a
significant decrease in corneal thickness (Fig. 1), probably
attributable to the deturgescent effect of the 20% dextran and
dehydration of the de-epithelialized cornea during cross-
linking. As might be expected, the concentration of riboflavin
over the ranges we used had no effect on corneal thickness.
In previous studies using an identical methodology, we have
shown that there are no differences at all between digestion
times in nonirradiated corneal controls that have not received
riboflavin drops and those soaked in riboflavin for 30
minutes.16,23 This allowed us, in this present study, to reduce
the number of control groups and use only completely de-
epithelialized, nontreated, nonirradiated corneas as a sole
control group. As we have documented previously,17,23 the
time required for complete digestion of the treated CXL
corneal discs was significantly longer than the untreated
controls, demonstrating the reproducibility of this technique
in detecting changes between CXL-treated and untreated
corneas. However, despite an evident trend for the higher-
concentration riboflavin-treated corneas to take longer to
digest completely, the differences between groups were not
significant. In contrast, the dry weight measurements after 10
days of digestion (Figs. 3A, 3B; Table 3) and to a lesser extent at
20 days (Fig. 4; Table 4), demonstrated significant differences
between the treatment groups, indicating that an increase in
riboflavin concentration from 0.05% to 3% results in a
progressive improvement in the resistance of cross-linked
corneas to enzymatic digestion. This suggests that measure-
ment of the time until digestion is complete is not sensitive
enough to detect subtle (but probably clinically important)
differences in CXL efficacy with differing protocols. Certainly,
in a previous study using this methodology to investigate SCXL
versus ACXL protocols,18 time to complete digestion showed
no differences, whereas dry weight measurements indicated
significant differences, with better results in SCXL.17 Clinical
investigations confirmed and supported such laboratory
findings of a reduced efficacy with ACXL.18,19
The similarity between runs 1 and 2 in terms of the average
dry weight measurements for each group after 10 days of
digestion confirmed our belief that the dry weight technique is
a less time-consuming and a more accurate and reproducible
technique for investigating CXL efficacy than are daily
measurements of corneal diameter (Fig. 3A, 3B; Table 3).
Over the ranges we tested, such outcomes support a dose-
response curve of riboflavin in CXL, with higher concentra-
tions, up to 0.3%, achieving greater efficacy. How these
results will transfer into clinical efficacy is undetermined until
clinical trials with higher concentrations are undertaken, but
they may have important implications. In this study, all
treatments were conducted using an ACXL technique of 9
mW/cm2 for 10 minutes (total energy dose 5.4 J/cm2), yet
manipulation of riboflavin dosage and hence stromal concen-
tration resulted in improved efficacy. This occurred without
oxygen supplementation or pulsing, which some authors,
both in laboratory23 and clinical studies,28,29 have hypothe-
sized may augment the CXL process, especially with ACXL
protocols. A riboflavin dose-response curve might suggest
that while oxygen and type II photochemical (aerobic)
reactions are undoubtedly important in the CXL process,24
type I photochemical (anaerobic) pathways, with direct
interaction between excited riboflavin triplets and stromal
proteins resulting in cross-linking, play a significant role and
may be augmented by increasing riboflavin concentrations
during CXL. As such, the efficacy of ACXL might be improved
not only by increasing the UVA dosage and perhaps the
addition of supplemental oxygen and/or pulsing but also by
simply increasing stromal riboflavin concentration. With
manipulation of such parameters, it might be possible with
ACXL to reduce the overall treatment time while maintaining
the same clinical efficacy as SCXL.
Such results may also have important implications for
epithelium-on CXL, where reports of reduced efficacy com-
pared to SCXL44 are likely to be related to limited riboflavin
absorption through the intact corneal epithelium and low
stromal riboflavin concentrations. A dose-response curve of
riboflavin with higher concentrations, at least up to 0.3%,
achieving greater efficacy would support such a hypothesis. It
is of note that by using two-photon fluorescence, we have
previously shown that stromal riboflavin concentrations with
currently commercially available protocols are only 10% to 30%
of that achieved with SCXL45 and that in laboratory studies,
manipulation of such epithelium-on protocols can result in
higher achieved stromal riboflavin concentrations46 and
resultant increased CXL efficacy.47
Finally, in the CXL process riboflavin has two basic
functions. As well as acting as a photosensitizer to produce
both oxygen singlets and riboflavin triplets to drive the CXL
process,22 it also absorbs the UVA photons within the anterior
corneal stromal to reduce UVA toxicity and potential damage to
internal ocular structures such as the endothelium.48 The use
of higher-strength riboflavin solutions resulting in increased
stromal riboflavin concentrations and therefore increased UVA
absorption within the anterior stroma, should theoretically
reduce the amount of UVA radiation reaching deeper layers of
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the cornea, reducing the risk of endothelial toxicity as well as
allowing for the possible treatment of thinner corneas.49 It is
interesting that while it might be supposed that increased
absorption of UVA photons within the anterior stroma by
higher riboflavin concentrations might result in an increased
but more superficial cross-linking effect, our dry weight results
of a significant increase in the mass of residual undigested
corneal tissue with increasing riboflavin concentration, while
there were no differences in disc diameter measurements,
suggest that this is probably not the case. We can postulate
from such results that more volume of tissue is being cross-
linked, including that in deeper stromal layers with higher
riboflavin concentrations, and that we are not merely getting a
more intense, but superficial effect, that one might expect not
to affect the dry weight measurements but to result in
differences in disc diameter measurements during the diges-
tion process.
CONCLUSIONS
Our results demonstrate a dose-response curve with increas-
ing riboflavin solution concentrations up to 0.3% achieving
greater CXL efficacy. This suggests that by simply increasing
the riboflavin concentration, at least within the limits we
tested, it may be possible to increase the efficacy of ACXL to
match that of SCXL. The use of higher concentrations of
riboflavin solution may also improve the outcomes of
epithelium-on CXL as well and allow the safe treatment of
thin corneas. Whether or not higher concentrations of
riboflavin in CXL may result in any adverse complications
(such as increased haze) is as yet undetermined, but this study
appears to support the commencement of clinical trials of
CXL with moderately increased higher riboflavin concentra-
tion solutions.
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